Shanghai Pharma proposes interim dividend, renews procurement agreement

Shanghai Pharmaceuticals Holding Co. has proposed an interim cash dividend of RMB1.20 (tax inclusive) for every ten shares for the first half of 2025, based on a total share capital of 3,708,361,809 shares. This distribution, totaling RMB445,003,417.08, represents 9.98% of the company's consolidated net profit attributable to shareholders for the period, which was RMB4,458,864,876.61. The proposal awaits shareholder approval.

Additionally, the company renewed its Procurement Framework Agreement with Wing Fat Printing, a connected person, for a term from January 1, 2026, to December 31, 2026. Under this agreement, Wing Fat Group will supply printed packaging materials for pharmaceutical products to Shanghai Pharma. The annual cap for this transaction is RMB90,000,000.

The board, including independent non-executive directors, views this continuing connected transaction as being in the ordinary course of business, on normal commercial terms, fair, and reasonable. Mr. YANG Qiuhua, a connected director, abstained from voting on the Procurement Framework Agreement.